EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

A Real‐World Cohort Study on the Association of the Use of Sodium‐Glucose Cotransporter‐2 Inhibitor With the Incidence of Chronic Kidney Disease ( CKD ) in Patients With Type 2 Diabetes Mellitus Without CKD Using the SingHealth Diabetes Registry

Yi Lin Ong iD, Zhong Hong Liew, Gek Hsiang Lim, Ngiap Chuan Tan, Ivan Wei Zhen Lee, Charles Jun Han Ng, Jason Chon Jun Choo, Chieh Suai Tan, Yong Mong Bee, Jia Liang Kwek

Diabetes, Obesity and Metabolism · 2026

DOI: 10.1111/dom.71137 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Yi Lin Ong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Renal Insufficiency, Chronic. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Kidney Foundation Singapore.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are well‐established for slowing chronic kidney disease (CKD) progression. However, their role in reducing the incidence of CKD in individuals with diabetes mellitus remains unclear.

Objectives

We evaluate the association of SGLT2i use with CKD incidence in a pre‐CKD multi‐ethnic Asian population with type 2 diabetes mellitus (T2D) with no CKD. Materials and Methods This retrospective cohort study analysed patients with T2D from 2016 to 2023 using the SingHealth Diabetes Registry. Patients with baseline estimated glomerular filtration rate (eGFR) ≥ 60 mL/min/1.73 m 2 and urinary albumin‐to‐creatinine ratio (uACR) < 30 mg/g were included. Cases and controls were matched based on age, gender, housing type, body mass index, HbA1c, baseline eGFR, renin‐angiotensin‐system inhibitors, metformin and glucagon‐like peptide‐1 receptor agonist using propensity score matching (PSM). Primary outcome was incident CKD and secondary outcomes included eGFR and uACR change over time. We used conditional logistic regression to estimate the odds ratio of incident CKD and mixed‐effects linear regression to assess eGFR change over time.

Results

Of 21 780 patients, 4450 patients (2225/group) were analysed after PSM. Median baseline eGFR were 103.58 mL/min/1.73 m 2 and 103.53 mL/min/1.73 m 2 in SGLT2i users and non‐users, respectively. SGLT2i users had lower CKD incidence (OR 0.36, 95% CI 0.31–0.42; p < 0.001) compared to non‐users. Longitudinal analysis demonstrated a slower rate of GFR decline and lower uACR increase over time in SGLT2i users.

Conclusion

SGLT2i use in individuals with T2D and preserved renal function was associated with lower CKD incidence, suggesting its potential preventive role in non‐CKD population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Sodium-Glucose Transporter 2 InhibitorsRenal Insufficiency, ChronicHumansFemaleMaleMiddle AgedRetrospective StudiesIncidenceRegistriesAgedGlomerular Filtration RateDiabetic NephropathiesCohort Studies

Stichwörter der Autor:innen

SGLT2 inhibitordiabetic nephropathyreal‐world evidencetype 2 diabetes

Substanzen

Sodium-Glucose Transporter 2 Inhibitors

Autor:innen und Institutionen

  • Department of Renal Medicine, Singapore General Hospital, Singapore, Singapore.
  • Health Services Research Unit, Singapore General Hospital, Singapore, Singapore.
  • SingHealth Polyclinics, Singapore Health Service, Singapore, Singapore.
  • Department of Renal Medicine, Sengkang General Hospital, Singapore, Singapore.
  • Department of Renal Medicine, Changi General Hospital, Singapore, Singapore.
  • Medicine Academic Clinical Programme, Singhealth Duke-NUS Academic Medical Centre, Singapore, Singapore.

ORCID-Profile: Yi Lin Ong

Förderung

  • National Kidney Foundation Singapore

Zitieren

APA

Ong, Y. L., Liew, Z. H., Lim, G. H., Tan, N. C., Lee, I. W. Z., Ng, C. J. H., Choo, J. C. J., Tan, C. S., Bee, Y. M., & Kwek, J. L. (2026). A Real‐World Cohort Study on the Association of the Use of Sodium‐Glucose Cotransporter‐2 Inhibitor With the Incidence of Chronic Kidney Disease ( CKD ) in Patients With Type 2 Diabetes Mellitus Without CKD Using the SingHealth Diabetes Registry. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71137

Vancouver

Ong YL, Liew ZH, Lim GH, Tan NC, Lee IWZ, Ng CJH, et al. A Real‐World Cohort Study on the Association of the Use of Sodium‐Glucose Cotransporter‐2 Inhibitor With the Incidence of Chronic Kidney Disease ( CKD ) in Patients With Type 2 Diabetes Mellitus Without CKD Using the SingHealth Diabetes Registry. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71137

BibTeX
@article{Ong2026,
  author = {Ong, Yi Lin and Liew, Zhong Hong and Lim, Gek Hsiang and Tan, Ngiap Chuan and Lee, Ivan Wei Zhen and Ng, Charles Jun Han and Choo, Jason Chon Jun and Tan, Chieh Suai and Bee, Yong Mong and Kwek, Jia Liang},
  title = {A Real‐World Cohort Study on the Association of the Use of Sodium‐Glucose Cotransporter‐2 Inhibitor With the Incidence of Chronic Kidney Disease ( CKD ) in Patients With Type 2 Diabetes Mellitus Without CKD Using the SingHealth Diabetes Registry},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2026},
  doi = {10.1111/dom.71137}
}
Kostenlos starten →